Bio-Rad Launches EconoFit Chromatography Column Packs

Wide Selection of Resins in New, Convenient Column Format to Support the Development of Protein Purification Workflows

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of EconoFit Low-Pressure Prepacked Chromatography Column Packs to support resin screening experiments in the development of protein purification workflows.

Bio-Rad’s range of EconoFit Columns provides a wide selection of resins in a prepacked format, allowing customers to simply screen resins and select the optimal chemistry for different target molecules. The new packs include mixed-mode, cation, and anion exchange resin columns, as well as a pack designed for His-tag protein purification. The convenient, easy-to-use and disposable column format is fully compatible with Bio-Rad’s NGC Chromatography Systems and other commonly used chromatography systems. Columns are available in 1 ml and 5 ml sizes.

“Similar resins can give different results for different target molecules, and with Bio-Rad’s EconoFit Column Packs our customers can easily perform resin scouting to identify the one which yields the best outcome for their chromatography application,” said Ertan Ozyamak, PhD, Bio-Rad Global Product Manager for lab-scale chromatography products. “Our columns deliver run-to-run uniformity to support preparative scale purifications and/or method development for new target proteins, as well as to improve existing workflows.”

To learn more about Bio-Rad’s EconoFit Chromatography Column Packs, please visit bio-rad.com/EconoFit.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 7,900 employees worldwide. Bio-Rad had revenues of $2.9 billion in 2021. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

< | >